Qube Research & Technologies (QRT)
AVTX icon

Qube Research & Technologies (QRT)’s Avalo Therapeutics AVTX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio AVTX Stock Details AVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-174,506
Closed -$2.61M – 3468
2026
Q1 		$2.61M Buy
174,506
+110,043
+171% +$1.72M ﹤0.01% 2018
2025
Q4 		$1.17M Buy
+64,463
New +$1.09M ﹤0.01% 2487
2022
Q3 		– Sell
-15
Closed -$22K – 2500
2022
Q2 		$22K Buy
+15
New +$20.1K ﹤0.01% 2254

Other funds holding AVTX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
AAA
Affinity Asset Advisors New York $2.21B AUM 431.26% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $21.7B AUM 79.24% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

Qube Research & Technologies (QRT)'s AVTX Position: Q2 2026 in Review

Qube Research & Technologies (QRT) sold out of Avalo Therapeutics (AVTX) in Q2 2026, closing a stake of 174,506 shares — an estimated $2.61M sold.

Qube Research & Technologies (QRT) first reported a position in AVTX in Q2 2022 and held it in 3 quarters. The position peaked at $2.61M in Q1 2026. 126 funds tracked by Wall St. Rank hold AVTX as of Q2 2026.

  • Qube Research & Technologies (QRT) reported no remaining Avalo Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 174,506 Avalo Therapeutics shares in Q2 2026, an estimated $2.61M.
  • Qube Research & Technologies (QRT) first reported a position in Avalo Therapeutics in Q2 2022 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s Avalo Therapeutics position peaked at $2.61M in Q1 2026.
  • 126 funds tracked by Wall St. Rank held Avalo Therapeutics as of Q2 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q2 2026, filed 14 Aug 2026.